HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed that ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an important early safety trial. Researchers have shared that the drug ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...

Did you know that there is a medication referred to as the birth control pill for HIV? HIV Pre-Exposure Prophylaxis (PrEP) is a pill that may cause a revolution in HIV prevention. If taken daily, ...

In this Oct. 7, 2019, file photo, a pharmacist displays the HIV prevention drugs Descovy, left and Truvada, right, at a pharmacy in Sacramento, Calif. A proposed federal policy aims to protect older ...